177Lu-Dotatate versus high-dose long-acting octreotide for the treatment of patients with advanced, grade 1-2, well-differentiated gastroenteropancreatic neuroendocrine tumours (XT-XTR008-3-01): an open-label, randomised, phase III trial

作者：Jianming Xu, Jie Chen, Shushu Song, Liping Song, Ruobing Wang, Jing Hao, Xin Du, Dongyan Cao, Yawen Gao, Xi Lan, Anthony D. Yang, Wenjun Miao, Hao Xu, Yan Chen, Lu Li, Hui Shi, Xianglin Yuan, F. Ye, Jian Wang, Nan Xu, Xu Han, Xudong Li, Ruiqi Huang, Tao� Zhang, Elizabeth Li, Ruobing Wang, Yue Zhou, Hao Chen, Xiaohua Zhu, Jue Zhao, Xin Su, Yuntao Cui, Peng Ren, Pengwei Wang · 发表于：Annals of Oncology · 年份：2025 · DOI：10.1016/j.annonc.2025.08.3758 · 被引用次数：5 · 研究领域：Neuroendocrine Tumor Research Advances、Lung Cancer Research Studies、Thyroid Cancer Diagnosis and Treatment